Study examines treatment options for those with operable non-small cell lung cancer, the leading cause of cancer deaths worldwide ...

Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.

The trial, which was funded by a National Institute for Health and Care Research (NIHR) Health Technology Assessment grant, ...

Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without ...

Almost one in five patients with advanced melanoma survived for five years after receiving lifileucel, with tumours shrinking ...

Inflammation fuels the high rate of cancer in people over 50, researchers find, leading them to test anti-inflammatories like allergy drugs to fight it.

An innovative new treatment for tackling some of the toughest stomach cancers has shown promise in a phase 2 clinical trial, ...

Results from a phase 3 clinical trial published in the New England Journal of Medicine, today (June 2nd) show that patients ...

A study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that combining the immunotherapy drug ...

With updated Phase I/Ib data in hand, Arcus will launch a Phase III trial as it aims to compete with Merck, whose drug ...

Results from a Phase III clinical trial published in the New England Journal of Medicine, show that patients with lung cancer ...

For Poolbeg Pharma, the question is not simply whether it can fund its ambitions, but whether its pipeline can justify them.